Quest Diagnostics Reports Strong Q4 & FY25 Results, Boosts Dividend 7.5%, and Authorizes $1 Billion Share Buyback

summarizeSummary

Quest Diagnostics reported strong Q4 and full-year 2025 financial results, provided positive 2026 guidance, increased its quarterly dividend by 7.5%, and authorized an additional $1 billion for share repurchases.

check_boxKey Events

• Strong Q4 and Full Year 2025 Financial Results

  Reported fourth quarter revenues of $2.81 billion (up 7.1%) and full year revenues of $11.04 billion (up 11.8%), with double-digit growth in both reported and adjusted diluted EPS for the full year.

• Positive Full Year 2026 Guidance

  Projected full year 2026 revenues between $11.70 billion and $11.82 billion, and adjusted diluted EPS between $10.50 and $10.70, reflecting continued confidence in business strengths.

• Quarterly Dividend Increased by 7.5%

  The Board of Directors authorized an increase in the quarterly cash dividend from $0.80 to $0.86 per share, marking the 15th consecutive year of dividend increases.

• Additional $1 Billion Share Repurchase Authorization

  The company increased its share repurchase authorization by $1 billion, bringing the total available for repurchase to approximately $1.4 billion, demonstrating a significant commitment to returning capital to shareholders.

auto_awesomeAnalysis

Quest Diagnostics announced robust financial performance for the fourth quarter and full year 2025, coupled with an optimistic outlook for 2026. The company's commitment to shareholder returns is evident through a significant 7.5% increase in its quarterly dividend, marking the 15th consecutive year of dividend growth. Furthermore, the Board authorized an additional $1 billion for its share repurchase program, bringing the total available authorization to approximately $1.4 billion. These actions, alongside strong operational results, signal management's confidence in the company's financial health and future growth prospects, especially as the stock trades near its 52-week high.